RT Journal Article
SR Electronic
T1 Extended Hematology-Oncology Fellowships in Bone Marrow Transplantation, Leukemia, Lymphoma, and Myeloma: What Proportion of Trainees Train and Remain at these Centers?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.14.23292614
DO 10.1101/2023.07.14.23292614
A1 Prasad, Vinay
YR 2023
UL http://medrxiv.org/content/early/2023/07/16/2023.07.14.23292614.abstract
AB Introduction A number of extra fellowships after traditional hematology oncology training have started in recent years, including training in lymphoma, myeloma, bone marrow transplantation, and leukemia. The benefit of this additional training is disputed.Methods and Materials We sought to quantify, from publicly reported data, what percentage of trainees either performed the extra year at the same location as they performed their fellowship– raising the question why they did not gain this training during the regular fellowship years– and what fraction stayed on at the same institution–raising the question of why the training was not performed on the job. Google and LinkedIn searches were performed to assemble the dataset.Results We examined 6 programs that made their graduate information public. We found 30% (17/56) of fellows either trained at the same institution or remained at the same institution as their extra fellowship.Conclusion Nearly 1 in 3 trainees that forgo an extra year do so in a context where they had opportunity to work at that center before or afterwards, raising the question as to whether the extra year was needed or could have been built into existing professional obligations.Competing Interest Statement(Research funding) Arnold Ventures (Royalties) Johns Hopkins Press, Medscape, and MedPage (Honoraria) Grand Rounds/lectures from universities, medical centers, non-profits, and professional societies. (Consulting) UnitedHealthcare and OptumRX. (Other) Plenary Session podcast has Patreon backers, YouTube, and Substack.Funding StatementThis study was funded by Arnold Ventures.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors